Daraxonrasib for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 1 interventional treatment study is evaluating oral daraxonrasib in participants with resectable pancreatic ductal adenocarcinoma. The study includes pre-surgery daraxonrasib treatment, surgery, adjuvant chemotherapy with or without radiation, optional adjuvant daraxonrasib, and follow-up. The protocol also includes research blood, stool, tissue, and de-identified data collection for correlative and future research.
Who Is on the Research Team?
Brandon Huffman, MD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that can be removed by surgery. Participants must be healthy enough for surgery and follow-up treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Adjuvant Chemotherapy
- Adjuvant Radiation Therapy
- Daraxonrasib
- Surgical Resection
Trial Overview
The study tests daraxonrasib, a new oral drug, given before surgery to remove the tumor. After surgery, patients get standard chemotherapy with or without radiation, and may also receive more daraxonrasib. The trial collects samples for research.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants receive oral daraxonrasib once daily at a predetermined dose for 12 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
Participants receive oral daraxonrasib once daily at a predetermined dose for 6 weeks before surgery, followed by a surgical planning interval, surgical resection, adjuvant chemotherapy with or without radiation per institutional standard and investigator discretion, and optional adjuvant daraxonrasib after completion of adjuvant therapy.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Revolution Medicines, Inc.
Industry Sponsor
The Mark Foundation for Cancer Research
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.